Albatira, Myline T.
HRN: 21-24-71 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/18/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
05/18/2022
05/24/2022
IVT
500mg 7 Doses
Q8
S/P Cesarean Section
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueReproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes